Complementary medicines in psychiatry: review of effectiveness and safety.
Ursula Werneke, Trevor Turner, Stefan Priebe
The British Journal of Psychiatry February 1, 2006 DOI: 10.1192/bjp.188.2.109 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review Peer reviewed |
|---|---|
| Keywords | Options Mental health Cognition Antidepressant properties Sedative effects Antidepressant treatments Herbal supplements: ginkgo St. john's wort Hydergine Passion flower Valerian S-adenosylmethionine Selenium Folate |
| Citations | 98 |
| Key findings | Ginkgo, hydergine, passion flower, valerian, St John's wort, s-adenosylmethionine, selenium, and folate show potential psychotropic benefits, but evidence for other substances is less conclusive. |
Abstract
The use of complementary medicines in those with mental health problems is well documented. However, their effectiveness is often not established and they may be less harmless than commonly assumed. To review the complementary medicines routinely encountered in psychiatric practice, their effectiveness, potential adverse effects and interactions. Electronic and manual literature search on the effectiveness and safety of psychotropic complementary medicines. Potentially useful substances include ginkgo and hydergine as cognitive enhancers, passion flower and valerian as sedatives, St John's wort and s-adenosylmethionine as antidepressants, and selenium and folate to complement antidepressants. The evidence is less conclusive for the use of omega-3 fatty acids as augmentation treatment in schizophrenia, melatonin for tardive dyskinesia and 18-methoxycoronaridine, an ibogaine derivative, for the treatment of cocaine and heroin addiction. Systematic clinical trials are needed to test promising substances. Meanwhile, those wishing to take psychotropic complementary medicines require appropriate advice.
Citations in the library
Cites 6
- A preliminary investigation of ibogaine: case reports and recommendations for further study. Journal of Substance Abuse Treatment 1994
- Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment. Pharmacology, Biochemistry, and Behavior June 1, 2003
- Plant derivatives in the treatment of alcohol dependency. Pharmacology, Biochemistry, and Behavior June 1, 2003
- Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine. Psychopharmacology September 1, 1996
- Properties of ibogaine and its principal metabolite (12-hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex. Neuroscience Letters June 2, 1995
and 1 more in the library